Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Immunology 5: Regulatory and Effector T Cells in Tumor Immunity

CD62Lhigh CD4+CD25+ Regulatory T cells primed in tumor-draining lymph nodes abrogate antitumor efficacy of effector T cells via B7-2 / CTLA-4 T-T interaction

Tooru Hiura, Hiroshi Kagamu, Satoru Miura, Akira Ishida, Koki Matsuyama, Hiroshi Tanaka, Junta Tanaka, Hirohisa Yoshizawa and Fumitake Gejyo
Tooru Hiura
Niigata University, Niigata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Kagamu
Niigata University, Niigata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoru Miura
Niigata University, Niigata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akira Ishida
Niigata University, Niigata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koki Matsuyama
Niigata University, Niigata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Tanaka
Niigata University, Niigata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junta Tanaka
Niigata University, Niigata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hirohisa Yoshizawa
Niigata University, Niigata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fumitake Gejyo
Niigata University, Niigata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2005
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 46, 2005

Abstract

2653

Tumor cells possess altered antigens that can be recognized by T cells, however, lack of danger signals and antigenic similarity to self-somatic cells, which tumor cells are derived from, engage the self-tolerance mechanism. This is one of the major reasons why anti-tumor immunity is hardly acquired. Secondary lymphoid organs are the places where antigen information carried by antigen presenting cells is converted to adaptive immune responses. We reported that antitumor effector T cells, which can mediate antitumor reactivity to cure established tumor in vivo, in LNs draining a growing skin tumor exclusively belonged to the CD62Llow subpopulation. Moreover, it was suggested that CD62Lhigh T cells contained regulatory subpopulation, because of our observation that the elimination of CD62Lhigh cells promotes generation of highly potent antitumor T cells upon CD3 stimulation. Recent studies revealed CD4+ T cells that constitutively express CD25 are playing a critical role in maintaining peripheral tolerance in numerous systems examined, such as infection, transplantation, autoimmunity, and tumor immunity. However, CD25 is also up-regulated on effector T cells upon TCR engagement before clonal expansion. Thus, it is difficult to distinguish regulatory T cells by CD25 expression, especially in LNs where T cell priming is going on, and this difficulty make it impossible to analyze how regulatory T cell are primed in LNs. Here, we analyze CD4+ tumor-draining LN T cells based on CD62L and CD25 expression and demonstrate that both antitumor effector T cells and regulatory T cells are primed in the same LNs draining growing skin tumors with different kinetics. CD62Llow antitumor effector T cells increased early in TDLN but were quickly taken over by CD62Lhigh CD4+CD25+ regulatory T cells, which are capable of abrogating the antitumor reactivity of CD62Llow LN T cells. Either CD62Llow CD4+CD25+ or CD62Llow CD4+CD25- LN T cells were proven to be antitumor effector T cells since they mediated antitumor efficacy when tranfered to skin tumor bearing mice, while the functions and phenotype of CD62Lhigh CD4+CD25- T cells were compatible with naïve T cells. FoxP3 expression was found to be unique for CD62Lhigh CD4+CD25+ LN T cells. CD62Lhigh CD4+CD25+ T cells could not be distinguished from CD62Llow CD4+CD25+ T cells by GITR, CTLA-4, or LAG3 expression. CD62Lhigh CD4+CD25+ LN T cells abolished proliferation and IFNγ production of CD62Llow effector T cells in the presence of immobilized anti-CD3 mAb. Unexpectedly, CD62Lhigh CD4+CD25+ regulatory T cells expressed B7-2. Blockade of CTLA-4/B7-2 interactions resulted in loss of regulatory activities. Our results indicated that CD62Lhigh CD4+CD25+ regulatory T cells primed in tumor-draining LNs abrogated the antitumor effector T cell functions via B7-2/CTLA-4 T-T interaction.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 65 (9 Supplement)
May 2005
Volume 65, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
CD62Lhigh CD4+CD25+ Regulatory T cells primed in tumor-draining lymph nodes abrogate antitumor efficacy of effector T cells via B7-2 / CTLA-4 T-T interaction
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
CD62Lhigh CD4+CD25+ Regulatory T cells primed in tumor-draining lymph nodes abrogate antitumor efficacy of effector T cells via B7-2 / CTLA-4 T-T interaction
Tooru Hiura, Hiroshi Kagamu, Satoru Miura, Akira Ishida, Koki Matsuyama, Hiroshi Tanaka, Junta Tanaka, Hirohisa Yoshizawa and Fumitake Gejyo
Cancer Res May 1 2005 (65) (9 Supplement) 624;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
CD62Lhigh CD4+CD25+ Regulatory T cells primed in tumor-draining lymph nodes abrogate antitumor efficacy of effector T cells via B7-2 / CTLA-4 T-T interaction
Tooru Hiura, Hiroshi Kagamu, Satoru Miura, Akira Ishida, Koki Matsuyama, Hiroshi Tanaka, Junta Tanaka, Hirohisa Yoshizawa and Fumitake Gejyo
Cancer Res May 1 2005 (65) (9 Supplement) 624;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Regulatory cells are involved in local immunosuppression in cervical cancer
  • An agonist anti-GITR antibody enhances effector and memory CD8 T cell responses and tumor immunity following xenogeneic DNA immunization against melanoma
  • Inhibition of tumor lysis between cytotoxic T cells of low and high recognition efficiency
Show more Immunology 5: Regulatory and Effector T Cells in Tumor Immunity
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement